Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

NCT06122493 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Tirelizumab
DRUG: Nab paclitaxel
DRUG: Carboplatin
RADIATION: Radiotherapy

Sponsor

Ruijin Hospital